Old Ayala Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Old Ayala Inc (AYLA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Old Ayala Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-39.3% annualized vs trailing 12 months).
- Peer revenue share: Old Ayala Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AYLA Sales vs. its Competitors, Q4 2022
Old Ayala Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Biotechnology & Pharmaceuticals industry grew revenue 22.1% year over year, combined, vs -90.8% for Old Ayala Inc. Old Ayala Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Old Ayala Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Old Ayala Inc | - | No | No | Yes |
| Competitors combined (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AYLA Stock Performance relative to its Competitors
Publicly Traded Peers of Old Ayala Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Old Ayala Inc |
7.78 | 0.69 |
 Lixte Biotechnology Holdings Inc |
54.57 | - |
| SUBTOTAL | 62.36 | 0.69 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Old Ayala Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Old Ayala Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Old Ayala Inc | 8 | - | - |
| Lixte Biotechnology Holdings Inc | 55 | - | -2,952,080 |
| PEERS TOTAL | 55 | - | -2,952,080 |
Old Ayala Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (159 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 13.01 % | 35.21 % (avg) | -22.2 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -1.12 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.29 % | 8.47 % (avg) | -8.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Old Ayala Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 0.8x | 5.1x | -4.3x |
| Return on Equity | -308.79 % | industry aggregate | -327.51 % |
| Return on Invested Capital | -148.39 % | -11.27 % (avg) | -137.12 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Old Ayala Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue Growth | 58.87 % | -5.45 % | -80.26 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | -40.11 % | -46.05 % | -148.39 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Old Ayala Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.29 % vs industry average 8.47 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Old Ayala Inc's dedicated Suppliers and Customers pages, not here.
Old Ayala Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 327.5 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-39.3% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Old Ayala Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Old Ayala Inc | 2.44 | 2.75 | - |
| Lixte Biotechnology Holdings Inc | 5.22 | 7.28 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Old Ayala Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Old Ayala Inc | Q4 2022 | -90.8 % | - |
| Lixte Biotechnology Holdings Inc | Q2 2026 | - | - |
| PEERS TOTAL | -90.8 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Old Ayala Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Old Ayala Inc | Q4 2022 | -90.8 % | - |
| Lixte Biotechnology Holdings Inc | Q2 2026 | - | - |
Old Ayala Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Old Ayala Inc | - | - | - |
| Lixte Biotechnology Holdings Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Old Ayala Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Old Ayala Inc | - | 11.24 |
| Lixte Biotechnology Holdings Inc | - | - |
| PEERS AVERAGE | - | 90.11 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.